buprenorphine subcutaneous extended Sublocade
Selected indexed studies
- Buprenorphine Extended-Release Injection for Subcutaneous Use (Sublocade(®)): An Overview for Psychiatric Advanced Practice Nurses. (J Psychosoc Nurs Ment Health Serv, 2025) [PMID:40626798]
- Subcutaneous Extended-Release Buprenorphine Use in Pregnancy. (Case Rep Obstet Gynecol, 2020) [PMID:32724686]
- Emergency Department-Initiated Buprenorphine for Opioid Use Disorder: A Randomized Clinical Trial. (JAMA, 2026) [PMID:41670966]
_Worker-drafted node — pending editorial review._
Connections
buprenorphine subcutaneous extended Sublocade is a side effect of
Sources
- Compact Arterial Monitoring Device Use in Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA): A Simple Validation Study in Swine. (2024) pubmed
- Buprenorphine Extended-Release Injection for Subcutaneous Use (Sublocade(®)): An Overview for Psychiatric Advanced Practice Nurses. (2025) pubmed
- Subcutaneous Extended-Release Buprenorphine Use in Pregnancy. (2020) pubmed
- Emergency Department-Initiated Buprenorphine for Opioid Use Disorder: A Randomized Clinical Trial. (2026) pubmed
- Subcutaneous Buprenorphine Extended-Release Use Among Pregnant and Postpartum Women. (2021) pubmed
- Subcutaneous Buprenorphine Extended-Release Use Among Pregnant and Postpartum Women. (2020) pubmed
- Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use: A Post Hoc Analysis of a Randomized Clinical Trial. (2024) pubmed
- Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. (2019) pubmed
- Evaluation of Drug-Drug Interaction Liability for Buprenorphine Extended-Release Monthly Injection Administered by Subcutaneous Route. (2021) pubmed
- Open-label, rapid initiation pilot study for extended-release buprenorphine subcutaneous injection. (2023) pubmed